HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Nasal and skin delivery of IC31(®)-adjuvanted recombinant HSV-2 gD protein confers protection against genital herpes.

Abstract
Genital herpes caused by herpes simplex virus type 2 (HSV-2) remains the leading cause of genital ulcers worldwide. Given the disappointing results of the recent genital herpes vaccine trials in humans, development of novel vaccine strategies capable of eliciting protective mucosal and systemic immune responses to HSV-2 is urgently required. Here we tested the ability of the adjuvant IC31(®) in combination with HSV-2 glycoprotein D (gD) used through intranasal (i.n.), intradermal (i.d.), or subcutaneous (s.c.) immunization routes for induction of protective immunity against genital herpes infection in C57BL/6 mice. Immunization with gD plus IC31(®) through all three routes of immunization developed elevated gD-specific serum antibody responses with HSV-2 neutralizing activity. Whereas the skin routes promoted the induction of a mixed IgG2c/IgG1 isotype profile, the i.n. route only elicited IgG1 antibodies. All immunization routes were able to induce gD-specific IgG antibody responses in the vaginas of mice immunized with IC31(®)-adjuvanted gD. Although specific lymphoproliferative responses were observed in splenocytes from mice of most groups vaccinated with IC31(®)-adjuvanted gD, only i.d. immunization resulted in a significant splenic IFN-γ response. Further, immunization with gD plus IC31(®) conferred 80-100% protection against an otherwise lethal vaginal HSV-2 challenge with amelioration of viral replication and disease severity in the vagina. These results warrant further exploration of IC31(®) for induction of protective immunity against genital herpes and other sexually transmitted infections.
AuthorsBenjamin Wizel, Josefine Persson, Karolina Thörn, Eszter Nagy, Ali M Harandi
JournalVaccine (Vaccine) Vol. 30 Issue 29 Pg. 4361-8 (Jun 19 2012) ISSN: 1873-2518 [Electronic] Netherlands
PMID22682292 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2012 Elsevier Ltd. All rights reserved.
Chemical References
  • Adjuvants, Immunologic
  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Drug Combinations
  • Herpes Simplex Virus Vaccines
  • IC31 adjuvant
  • Immunoglobulin G
  • Oligodeoxyribonucleotides
  • Oligopeptides
  • Viral Envelope Proteins
  • glycoprotein D-herpes simplex virus type 2
  • Interferon-gamma
Topics
  • Adjuvants, Immunologic (administration & dosage)
  • Administration, Intranasal
  • Animals
  • Antibodies, Neutralizing (blood)
  • Antibodies, Viral (blood)
  • Drug Combinations
  • Female
  • Herpes Genitalis (immunology, prevention & control)
  • Herpes Simplex Virus Vaccines (immunology)
  • Herpesvirus 2, Human (immunology)
  • Immunity, Mucosal
  • Immunoglobulin G (blood)
  • Injections, Intradermal
  • Injections, Subcutaneous
  • Interferon-gamma (immunology)
  • Mice
  • Mice, Inbred C57BL
  • Oligodeoxyribonucleotides (administration & dosage)
  • Oligopeptides (administration & dosage)
  • Spleen (immunology)
  • T-Lymphocytes (immunology)
  • Vagina (immunology)
  • Viral Envelope Proteins (immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: